Galderma
Galderma is a dermatology-focused company whose brands include Cetaphil, spanning consumer skincare and prescription dermatology.
- 8.9k
- Public
- Zug, CH
Galderma is a dermatology-focused company whose brands include Cetaphil, spanning consumer skincare and prescription dermatology.
galderma.comCrawled Oct 15, 2026
Nestlé Skin Health hosted aging experts at the IAGG World Congress to discuss skin wellness in aging and the potential of accessible skin health solutions to support independence.
Lausanne, 24 May 2017 - Nestlé Skin Health is delighted to announce that 2017 marks the 70th anniversary of Cetaphil, their dermatologically formulated skincare range which is clinically proven to strengthen and protect even the most sensitive skin ensuring healthy skin.
Galderma enrolled the first patient in a Phase IIb trial evaluating nemolizumab in patients with moderate-to-severe atopic dermatitis and severe pruritus inadequately controlled by topical treatments.
Nestlé Skin Health released Itch Tracker, an application that collects data on scratching during sleep and uses the Apple Watch accelerometer.
News room landing page
Galderma
Galderma reports record first-half 2026 net sales of USD 3.134 billion, representing 24.6% year-on-year growth at constant currency. Growth spans all three product categories, and the company raises its full-year 2026 net sales growth guidance to 19–21% at constant currency.
Jul 2026GaldermaNews article
Galderma reports record net sales of $5.207 billion for full-year 2025, exceeding $5 billion for the first time. Core EBITDA reaches $1.211 billion, up 18.9% at constant currency.
Mar 2026GaldermaNews article
Galderma appoints Luigi La Corte as chief financial officer, effective May 1, 2026. He succeeds Thomas Dittrich, who has served as CFO since October 2019.
Feb 2026GaldermaNews article
Galderma receives U.S. FDA approval for Nemluvio (nemolizumab) as a treatment for adults with prurigo nodularis. The pre-filled pen is the first approved monoclonal antibody specifically inhibiting IL-31 signaling, and its approval is based on the phase III OLYMPIA clinical trial program.
Aug 2024GaldermaNews article